|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||11.40 - 11.85|
|52 Week Range||7.40 - 18.93|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||24.53|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.